FRANKLIN LAKES, N.J–(PRNewswire, Jan. 7, 2015)–BD Medical, a segment of BD (Becton, Dickinson and Company) BDX, +1.58% a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the BD™ Intelliport® Medication Management System, the first-of-its-kind medication management solution for manual IV bolus injections. The Intelliport System is the first and only solution to provide real-time drug identification, dose measurement and allergy detection at the point of injection, while wirelessly sending captured information directly into the patient’s electronic medical record (EMR) following medication administration.
With this new FDA clearance, BD can offer healthcare workers advanced, smart-injection-site functionality and access to medication administration information at the point-of-care. By combining the Intelliport System’s unique IV access site sensor with a rechargeable, wireless base and touch-screen tablet technology, integrated with hospital information systems, essential medical information can be recorded instantaneously, following patients throughout their perioperative stay. The Intelliport System is expected to be commercially available in spring 2015.